QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)

Vericel (VCEL) Competitors

$43.74
-0.12 (-0.27%)
(As of 04:38 PM ET)

VCEL vs. DNLI, CGON, BEAM, KYMR, DNA, IMCR, SANA, FUSN, RXRX, and NMRA

Should you be buying Vericel stock or one of its competitors? The main competitors of Vericel include Denali Therapeutics (DNLI), CG Oncology (CGON), Beam Therapeutics (BEAM), Kymera Therapeutics (KYMR), Ginkgo Bioworks (DNA), Immunocore (IMCR), Sana Biotechnology (SANA), Fusion Pharmaceuticals (FUSN), Recursion Pharmaceuticals (RXRX), and Neumora Therapeutics (NMRA). These companies are all part of the "biological products, except diagnostic" industry.

Vericel vs.

Denali Therapeutics (NASDAQ:DNLI) and Vericel (NASDAQ:VCEL) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk, community ranking and dividends.

Vericel has a net margin of -1.61% compared to Vericel's net margin of -36.51%. Denali Therapeutics' return on equity of -1.55% beat Vericel's return on equity.

Company Net Margins Return on Equity Return on Assets
Denali Therapeutics-36.51% -13.50% -11.38%
Vericel -1.61%-1.55%-1.02%

In the previous week, Denali Therapeutics had 1 more articles in the media than Vericel. MarketBeat recorded 5 mentions for Denali Therapeutics and 4 mentions for Vericel. Denali Therapeutics' average media sentiment score of 1.02 beat Vericel's score of 0.87 indicating that Vericel is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Denali Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Vericel
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

92.9% of Denali Therapeutics shares are held by institutional investors. 7.9% of Denali Therapeutics shares are held by insiders. Comparatively, 5.2% of Vericel shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Denali Therapeutics currently has a consensus target price of $41.22, indicating a potential upside of 148.33%. Vericel has a consensus target price of $46.40, indicating a potential upside of 5.79%. Given Vericel's higher possible upside, equities analysts clearly believe Denali Therapeutics is more favorable than Vericel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Denali Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
3.00
Vericel
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

Denali Therapeutics received 103 more outperform votes than Vericel when rated by MarketBeat users. Likewise, 67.38% of users gave Denali Therapeutics an outperform vote while only 62.38% of users gave Vericel an outperform vote.

CompanyUnderperformOutperform
Denali TherapeuticsOutperform Votes
438
67.38%
Underperform Votes
212
32.62%
VericelOutperform Votes
335
62.38%
Underperform Votes
202
37.62%

Denali Therapeutics has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Comparatively, Vericel has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500.

Vericel has lower revenue, but higher earnings than Denali Therapeutics. Vericel is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Denali Therapeutics$330.53M6.99-$145.22M-$1.08-15.37
Vericel$197.52M10.74-$3.18M-$0.09-487.28

Summary

Denali Therapeutics beats Vericel on 9 of the 17 factors compared between the two stocks.

Get Vericel News Delivered to You Automatically

Sign up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VCEL vs. The Competition

MetricVericelBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$2.24B$2.56B$4.81B$7.49B
Dividend YieldN/A2.31%2.99%4.01%
P/E Ratio-487.2815.39170.0913.87
Price / Sales10.74298.992,390.5489.32
Price / Cash2,625.13140.1846.7734.79
Price / Book9.273.714.584.19
Net Income-$3.18M-$45.93M$103.72M$214.15M
7 Day Performance-8.43%-7.53%-3.79%-3.31%
1 Month Performance-3.88%-9.55%-5.29%-3.81%
1 Year Performance39.64%2.82%7.30%3.74%

Vericel Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DNLI
Denali Therapeutics
3.8264 of 5 stars
$17.34
-2.8%
$41.22
+137.7%
-33.9%$2.41B$330.53M-16.06445Gap Down
CGON
CG Oncology
0.6315 of 5 stars
$36.47
-3.1%
$61.75
+69.3%
N/A$2.43B$200,000.000.0061
BEAM
Beam Therapeutics
3.0258 of 5 stars
$25.70
flat
$41.00
+59.5%
-21.8%$2.10B$377.71M-13.53436Short Interest ↓
KYMR
Kymera Therapeutics
0.8154 of 5 stars
$33.93
-1.3%
$39.89
+17.6%
+0.6%$2.07B$78.59M-13.46187Gap Down
DNA
Ginkgo Bioworks
1.256 of 5 stars
$0.92
-3.2%
$2.20
+139.8%
-26.0%$1.97B$251.46M-1.951,218Gap Down
IMCR
Immunocore
2.1769 of 5 stars
$53.37
-3.9%
$80.55
+50.9%
-7.0%$2.66B$249.43M-46.01497
SANA
Sana Biotechnology
2.2731 of 5 stars
$8.41
-1.6%
$11.67
+38.7%
+39.3%$1.85BN/A-5.72328News Coverage
FUSN
Fusion Pharmaceuticals
0.6978 of 5 stars
$21.26
-0.1%
$20.25
-4.8%
+418.3%$1.80B$2.07M-14.46101Analyst Report
RXRX
Recursion Pharmaceuticals
2.521 of 5 stars
$7.57
-2.8%
$12.75
+68.4%
+24.6%$1.78B$44.58M-4.88500Insider Selling
NMRA
Neumora Therapeutics
0.7799 of 5 stars
$10.96
-2.1%
$22.57
+105.9%
N/A$1.74BN/A0.00124Positive News

Related Companies and Tools

This page (NASDAQ:VCEL) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners